[HTML][HTML] Multi-omics and management of follicular carcinoma of the thyroid
TE Luvhengo, I Bombil, A Mokhtari, MS Moeng… - Biomedicines, 2023 - mdpi.com
Follicular thyroid carcinoma (FTC) is the second most common cancer of the thyroid gland,
accounting for up to 20% of all primary malignant tumors in iodine-replete areas. The …
accounting for up to 20% of all primary malignant tumors in iodine-replete areas. The …
[HTML][HTML] Impact of lung metastasis versus metastasis of bone, brain, or liver on overall survival and thyroid cancer-specific survival of thyroid cancer patients: a …
M Zhong, FZ Khan, X He, L Cui, K Lei, M Ge - Cancers, 2022 - mdpi.com
Simple Summary Patients with thyroid cancer have different survival rate based on their
cancer type and the organs affected by the metastases. About 88% of the patients with …
cancer type and the organs affected by the metastases. About 88% of the patients with …
Neutrophil-to-lymphocyte ratio as an independent factor for worse prognosis in radioiodine refractory thyroid cancer patients
N Treistman, LBCP Cavalcante, F Gonzalez… - Endocrine, 2023 - Springer
Purpose This study aimed to evaluate neutrophil to lymphocyte ratio (NLR) as a laboratory
biomarker in radioactive iodine-refractory (RAIR) locally advanced and/or metastatic …
biomarker in radioactive iodine-refractory (RAIR) locally advanced and/or metastatic …
[HTML][HTML] Multimodality MRI-based radiomics for aggressiveness prediction in papillary thyroid cancer
Z Dai, R Wei, H Wang, W Hu, X Sun, J Zhu, H Li… - BMC medical …, 2022 - Springer
Objective To investigate the ability of a multimodality MRI-based radiomics model in
predicting the aggressiveness of papillary thyroid carcinoma (PTC). Methods This study …
predicting the aggressiveness of papillary thyroid carcinoma (PTC). Methods This study …
[HTML][HTML] Management of hypertension during lenvatinib for advanced thyroid cancer: a suggested diagnostic and therapeutic algorithm
Background Hypertension (HTN) is the most frequent adverse event during treatment with
lenvatinib (LEN), but data on its best management are limited. Aim The objective of this …
lenvatinib (LEN), but data on its best management are limited. Aim The objective of this …
[Retracted] Risk Factors for Pulmonary Metastasis in Differentiated Thyroid Carcinoma Patients and the Significance of Changes in Matrix Metalloproteinase 13 and …
X Zhang, Z Lu, G Zhang, S Li, A Zhao… - Contrast Media & …, 2022 - Wiley Online Library
This work aims to explore the risk factors of lung metastasis (LM) in differentiated thyroid
cancer (DTC)(LM‐DTC) and the effect of treatment and to detect the relationship between …
cancer (DTC)(LM‐DTC) and the effect of treatment and to detect the relationship between …
[HTML][HTML] Prediction of papillary thyroid metastases to the central compartment: proposal of a model taking into consideration other thyroid conditions
Q Chen, X Ye, K Wang, H Shen - Frontiers in Endocrinology, 2023 - frontiersin.org
Objective To construct risk prediction models for cervical lymph node metastasis (CLNM) of
papillary thyroid carcinoma (PTC) under different thyroid disease backgrounds and to …
papillary thyroid carcinoma (PTC) under different thyroid disease backgrounds and to …
Long-term outcomes and prognostic factors of patients with lung metastases from differentiated thyroid cancer after radioiodine therapy in Japan
N Akatani, H Wakabayashi, D Kayano, A Inaki… - Endocrine …, 2023 - jstage.jst.go.jp
Long-term survival in patients with differentiated thyroid cancer (DTC) and lung metastasis
remains unexplored in Japan. This study aimed to investigate the long-term survival and …
remains unexplored in Japan. This study aimed to investigate the long-term survival and …
[PDF][PDF] Multi-omics and management of follicular carcinoma of the thyroid. Biomedicines 2023; 11: 1217
TE Luvhengo, I Bombil, A Mokhtari, MS Moeng… - 2023 - researchgate.net
Follicular thyroid carcinoma (FTC) is the second most common cancer of the thyroid gland,
accounting for up to 20% of all primary malignant tumors in iodine-replete areas. The …
accounting for up to 20% of all primary malignant tumors in iodine-replete areas. The …